Triple-Negative and BRCA-Mutated Metastatic Breast Cancer

Slides:

Advertisements

Similar presentations

Efficacy of BSI-201, a PARP-Inhibitor in combination with Gemcitabine/Carboplatin in Triple Negative Breast Cancer: Randomized.

Advertisements

Triple negative breast cancer

A trial for women with –‘Triple negative’ breast cancer (TNBC) –Localised to breast +/- lymph nodes –Recommended standard treatment involves NEPTUNE Taxane.

Trials of Adjuvant Trastuzumab in HER2+ Early-Stage Breast Cancer Trial Study Regimen No. of Patients Disease-Free Survival (%) Hazard Ratio P-Value Overall.

Educational Objectives Metastatic Breast Cancer: Scope of the Problem.

Graph paper template R2 이지훈 / Prof. 맹치훈 Lancet Oncol 2012; 13:

Clinical and Research Updates in Gynecologic Oncology

Case Discussion: Second Opinion

Biology and Treatment of Breast Cancer

Adjuvant Therapy of Triple Negative Breast Cancer

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

Finding the Right Fit: Personalizing Treatment in Metastatic Castration-Resistant Prostate Cancer.

Triple negative breast cancer 21st Annual NOCR Meeting

Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.

Optimizing Combination Endocrine Therapy in HR-Positive Advanced Breast Cancer.

Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination With Chemotherapy in Early-Stage TNBC CCO Independent Conference Highlights*

Triple negative breast cancer in Asia: An insider’s view

Endocrine Combinations in HR-Positive MBC: The Future Is Now

The Use of PARP Inhibitors in Breast Cancer: Challenges and Opportunities.

Metastatic HER2+ Breast Cancer: Resistance

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

Updates and Insights on the Medical Science of Prostate Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

An Introduction to DNA Damage Repair in Cancer: Beyond PARP

Steps to Optimizing Outcomes in Patients With Advanced Prostate Cancer

Perspectives on Triple-Negative Breast Cancer

PARP Inhibition: The New Frontier in Recurrent Ovarian Cancer

Advanced NSCLC Without Actionable Mutations

Her2-positive breast cancer: updating current best practice

BRCA, HRR Deficiency, and PARP Inhibitors

Overall Program Goals. Overall Program Goals Current Approaches.

Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.

PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update

Navigating New Treatment Landscapes in HR-Positive, HER2-Negative Metastatic Breast Cancer.

Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?

Program Goals. The Clinical Impact of Second-Generation Antihormonal Therapy in the Treatment of mCRPC.

PARP Inhibitors and Cancer: What Do You Need to Know?

For the Urologist by the Urologist: Essential Concepts in Managing mCRPC.

Optimizing Management of Advanced Bladder Cancer

Managing gBRCA-Positive Metastatic Breast Cancer

Individualizing Care in Ovarian Cancer

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

Optimizing Neoadjuvant Treatment for Primary Breast Cancer

Immunotherapy for cSCC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Advancing Care Across the Spectrum of Pancreatic Cancer

Breast Cancer Statistics

PARP Inhibitors and Ovarian Cancer: What Did Data From Washington, DC, Tell Us?

Chapter 3 Treatment guidelines for NSCLC that does not have targetable driver mutations.

PARP Inhibitors.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Introduction Advanced Hormone Receptor-Positive Breast Cancer

Molecular Testing in Ovarian Cancer: Is the Time Now?

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion.

Practical Guidance on the Management of Pan-Negative NSCLC

(A) Safety profile overview.

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.

What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Objective response rate in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.

Evaluating the Totality of Evidence

Clinical Focus.

The Nurse View.

Uncovering the Right Sequence

Optimizing Patient Outcomes in Metastatic Triple-Negative Breast Cancer.

Presentation transcript:

Triple-Negative and BRCA-Mutated Metastatic Breast Cancer

TNBC Overview

TNBC Subtypes

Case Overview

Recommended Regimens for the First-Line Treatment of MBC

TNT Study: Carboplatin vs Docetaxel in Advanced TNBC or BRCA1/2-Positive MBC

tnAcity: Phase 2 Trial of Nab-Paclitaxel and Carboplatin in Front-Line Metastatic TNBC

Androgen Signaling and TNBC

Targeting the AR Pathway in TNBC Bicalutamide

Phase 2 Single-Arm Study of Bicalutamide in AR-Positive, ER-Negative MBC

Targeting the AR Pathway in TNBC Enzalutamide

Phase 2 Study of Enzalutamide in Advanced AR-Positive TNBC

ENDEAR: Phase 3 Trial of Enzalutamide-Positive Paclitaxel in Advanced Diagnostic-Positive TNBC

UCBG 12-1: Phase 2 Trial of Abiraterone Acetate-Prednisone in Advanced AR-Positive TNBC

Phase 1b/2 Data for Pembrolizumab in Advanced TNBC

Ongoing Studies of Immune Checkpoint Inhibitors in Advanced TNBC

PARP Inhibitors in TNBC

Randomized Phase 2 Trial of Veliparib and Cyclophosphamide in Advanced TNBC

Phase 1 Trial of Olaparib and Paclitaxel in TNBC

PARP Inhibitors in BRCA-Mutated MBC

Phase 2 Study of Lurbinectedin in BRCA-Mutated MBC

Antibody-Drug Conjugates in Development for TNBC

Concluding Remarks